8-K
filed February 21, 2023, 6:59 PM ET
ticker OSRH
CIK 0001840425
other material
confidence high
sentiment neutral
materiality 0.50
Bellevue Life Sciences Acquisition Corp. closes IPO and full over-allotment, raising $69M
OSR Holdings, Inc.
- IPO of 6M units at $10/unit closed Feb 14, 2023; over-allotment of 900K units exercised in full, total 6.9M units.
- Gross proceeds of $69M from IPO and over-allotment; $70.2M placed in trust account including private placement.
- Appointed five independent directors: Dr. Steven G. Reed (Chairman), Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, Mr. Jin Whan Park.
- Units trade on Nasdaq under BLACU; common, warrants, rights under BLAC, BLACW, BLACR.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Steven G. Reed was appointed as Chairman of the Board at OSR Holdings, Inc..
- Action
- appointed
- Role
- Chairman of the Board
Exact text from the filing
On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Rad Roberts was appointed as Director at OSR Holdings, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. In Chul Chung was appointed as Director at OSR Holdings, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mr. Jin Whan Park was appointed as Director at OSR Holdings, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mr. Hosun Euh was appointed as Director at OSR Holdings, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.